文献速递冠心病瓣膜病与结构性心脏病

成人川崎病的管理

Management of Kawasaki disease in adults.
PubMed 文献 · Heart · 2017-07-27

川崎病是美国最常见的儿童血管炎,也是发达国家儿童获得性心脏病的首要病因,多数在5岁前起病,成人心内科医生常不熟悉其病理生理。该病好发于冠状动脉,中大型冠状动脉瘤患者终生并发症风险高,炎症级联导致内皮功能障碍和血管壁损伤,进而形成动脉瘤。2017年AHA和2014年JCS指南强调需通过心脏负荷试验和无创影像学严格随访,以发现可能引起心肌缺血和梗死的进行性狭窄、血栓和管腔闭塞;由于机制不同,川崎病所致冠状动脉病变应采用不同于动脉粥样硬化性冠心病的药物和非药物治疗方案。

要点

  • 川崎病好发于冠状动脉,中大型冠状动脉瘤患者终生并发症风险高。
  • 血管重塑和血栓层叠可致管腔假性正常化,但不代表病变消退或风险降低。
  • 需按AHA和JCS指南用负荷试验和无创影像学严格随访冠状动脉病变。

核心结论

  • 川崎病相关冠状动脉病变需与动脉粥样硬化性冠心病区分管理,并依据AHA和JCS指南长期随访。

研究设计与样本

  • 本文为综述,围绕成人川崎病的管理进行论述,并比较2017年AHA与2014年JCS指南的差异。

主要发现

  • 川崎病好发于冠状动脉,中大型冠状动脉瘤患者终生并发症风险高。
  • 炎症级联导致内皮功能障碍和血管壁损伤,引起动脉瘤样扩张。
  • 血管重塑和血栓层叠可致管腔假性正常化,但不一定代表疾病消退或未来并发症风险降低。
  • 川崎病患病率呈上升趋势,随着患者进入成年,成人心内科医生需更关注该病。

关键数值与推荐

  • 2017年AHA和2014年JCS指南强调,川崎病需通过心脏负荷试验和无创影像学严格随访,以检测进行性狭窄、血栓和管腔闭塞。
  • 川崎病所致冠状动脉病变应采用不同于动脉粥样硬化性冠心病的药物和非药物治疗方案。

临床怎么用

  • 对成人川崎病患者应询问儿童期病史,并按指南进行心脏负荷试验和无创影像学随访。
  • 发现冠状动脉瘤或管腔假性正常化时,不应视为疾病消退而放松随访。
  • 川崎病相关冠状动脉病变的治疗应区别于动脉粥样硬化性冠心病。

局限性

  • 本文为综述,未报告原始研究数据。
  • 成人心内科医生对川崎病病理生理不熟悉,且从青少年到成人的过渡期管理存在障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kawasaki disease is the most common childhood vasculitis in the USA and the most common cause of acquired cardiac disease in children in developed countries. Since the vast majority of Kawasaki disease initially presents at <5 years of age, many adult cardiologists are unfamiliar with the pathophysiology of this disease. This vasculitis has a predilection for coronary arteries with a high complication rate across the lifespan for those with medium to large coronary artery aneurysms. An inflammatory cascade produces endothelial dysfunction and damage to the vascular wall, leading to aneurysmal dilatation. Later, pseudonormalisation of the vascular lumen occurs through vascular remodelling and layering thrombus, but this does not necessarily indicate resolution of disease or reduction of risk for future complications. There is a growing prevalence of Kawasaki disease, making it increasingly relevant for adult cardiologists as this population transitions into adulthood. As the 2017 American Heart Association (AHA) and 2014 Japanese Circulation Society (JCS) guidelines emphasise, Kawasaki disease requires rigorous follow-up with cardiac stress testing and non-invasive imaging to detect progressive stenosis, thrombosis and luminal occlusion that may lead to myocardial ischaemia and infarction. Due to differences in disease mechanisms, coronary disease due to Kawasaki disease should be managed with different pharmacological and non-pharmacological treatment algorithms than atherosclerotic coronary disease. This review addresses gaps in the current knowledge of the disease and its optimal treatment, differences in the AHA and JCS guidelines, targets for future research and obstacles to transition of care from adolescence into adulthood.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Denby KJ, Clark DE, Markham LW, et al. Management of Kawasaki disease in adults. Heart. 2017. PMID: 28751537. doi:10.1136/heartjnl-2017-311774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。